Nanoscale drug carriers play an important role in regulating the delivery, permeability, and retention of the drugs. Although various carriers have been used to encapsulate anticancer drugs, natural biomaterials are of great benefit for delivery and controlled release of drugs and their momentous activity in mice induced animal model.
We used the co-precipitation system to synthesize silymarin-iron composite nanoparticles for delivery and controlled release. Moreover, loaded particles were evaluated for its antiproliferation, cell cycle arrest, in vivo antitumor activity and apoptosis induction in triple negative breast cancer cells.
(TNBC). DLS and TEM analysis confirmed that the size of synthesized iron oxide nanoparticles are about 60nm and extremely crystalline, spherical in nature. FTIR analysis confirmed that the silymarin molecules were conjugated with PEG coated iron oxide nanoparticles. X-ray diffraction pattern indicated that the iron nanoparticles were highly pure nature. Silymarin loaded nanoparticles showed a controlled release profile in response to diverse levels of pH. The particle mediated cytotoxicity was determined in MDA-MB-231 cancer cells and not found any adverse effect in normal cell HBL-100. We found that significant cell cycle arrest at various phases in the treated cancer cells and subsequent apoptotic cell death was evidenced with AO/EtBr, DAPI and PI of fluorescence microscopic analysis. TUNEL assay evidenced that DNA damage occurred in the treated cells. It could able to regulate the apoptotic and anti-apoptotic proteins. Moreover, the nanocomplexes are significantly reducing the tumor volume in tumor induced mice model.
Our findings have clearly demonstrated that silymarin loaded iron oxide nanoparticles could have efficiently deliver the drug of interest at the site of inflammation, initiate and execute the mitochondrial mediated apoptotic process in both in vitro and in vivo model.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.